amlodipine has been researched along with Coronary Artery Disease in 59 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy." | 9.51 | Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. ( Agrawal, S; Anand, J; Bachani, D; Doshi, M; Gaikwad, VB; Halder, SK; Kinholkar, B; Kumar, DA; Kumbhar, A; Mathur, R; Mehta, S; Sarkar, G; Sharma, A, 2022) |
| "Long-term therapy with a combination of perindopril and amlodipine has shown a beneficial effect on the morbidity and mortality of patients with stable coronary artery disease (SCAD) and hypertension." | 9.22 | Short-Term Cardioprotective Effects of the Original Perindopril/Amlodipine Fixed-Dose Combination in Patients with Stable Coronary Artery Disease: Results of the PAPA-CAD Study. ( Dézsi, CA; Forster, T, 2016) |
| "Amlodipine, commonly used for relief of ischemic symptoms in coronary artery disease (CAD), may affect clopidogrel-induced antiplatelet effects." | 9.20 | Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable ( Angiolillo, DJ; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Rollini, F; Rosano, G; Vitale, C, 2015) |
| "Combination therapy with benazepril 40 mg and amlodipine 10 mg (B+A) has been shown to be more effective than benazepril 40 mg and hydrochlorothiazide (HCTZ) 25 mg (B+H) in reducing cardiovascular (CV) events in high-risk patients with stage 2 hypertension with similar blood pressure reductions." | 9.17 | Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. ( Bakris, G; Briasoulis, A; Dahlof, B; Hester, A; Hua, T; Jamerson, K; Kelly, RY; Pitt, B; Weber, MA; Zappe, D, 2013) |
| "The purpose of this post hoc subgroup analysis was to compare the incidence of major adverse cardiovascular events (MACE) of patients treated with candesartan and amlodipine with that of those with candesartan and non-amlodipine CCBs in hypertensive patients with coronary artery disease (CAD)." | 9.17 | Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study. ( Hagiwara, N; Haruta, S; Kawada-Watanabe, E; Koyanagi, R; Ogawa, H; Takagi, A; Yamaguchi, J, 2013) |
| "In many countries, combination therapy with amlodipine and atorvastatin is indicated for the treatment of patients with hypertension and hypercholesterolemia." | 9.15 | Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: combination therapy and adiponectin. ( Cheung, BM; Lam, KS; Li, M; Tse, HF; Xu, A, 2011) |
| "To estimate the potential savings in overall cardiovascular disease (CVD) treatment costs for the US population with coronary artery disease (CAD) resulting from the use of amlodipine." | 9.10 | Economic benefits of amlodipine treatment in patients with coronary artery disease. ( Arikian, S; Arocho, R; Casciano, J; Casciano, R; Chen, J; Doyle, JJ; Kugel, H, 2002) |
| "A literature search was performed in PubMed/MEDLINE to identify articles published in English between 1988 and March 2008 describing clinical trials, particularly outcome trials, or mechanisms of therapeutic action relevant to the use of combination therapy in patients with hypertension or stable coronary artery disease with an ACE inhibitor (perindopril) and a calcium channel blocker (amlodipine)." | 8.84 | Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine. ( Ferrari, R, 2008) |
| "In the present quantitative overview of outcome trials, we investigated the efficacy of amlodipine or angiotensin receptor blockers in the prevention of stroke and myocardial infarction in patients with hypertension, coronary artery disease, or diabetic nephropathy." | 8.84 | Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. ( Franklin, SS; Li, Y; Safar, M; Wang, JG, 2007) |
| "to compare the antianginal and pulse slowing effects, the impact on the ectopic myocardial activity as well as the safety of the treatment with beta - adrenoblocker bisoprolol, calcium antagonist verapamil and the combination of bisoprolol with amlodipine in patients with stable angina (SA) and bronchial asthma (BA)." | 7.91 | [Possibilities of cardioselective beta - blocker bisoprolol therapy in patients having coronary artery disease and bronchial asthma]. ( Grigorieva, NY; Ilyushina, TP; Yashina, EM, 2019) |
| "This study assessed adherence to and the safety, tolerance, and effectiveness of the perindopril/amlodipine FDC in Greek patients with hypertension and stable coronary artery disease (CAD) over a 4-month period." | 7.85 | Adherence to Treatment, Safety, Tolerance, and Effectiveness of Perindopril/Amlodipine Fixed-Dose Combination in Greek Patients with Hypertension and Stable Coronary Artery Disease: A Pan-Hellenic Prospective Observational Study of Daily Clinical Practice ( Kotsis, VT; Liakos, CI; Papadopoulos, DP, 2017) |
| "The objective of this analysis was to calculate the cost-effectiveness of amlodipine therapy in patients with coronary artery disease in Sweden." | 7.71 | A cost-effectiveness evaluation of amlodipine usage in patients with coronary artery disease in Sweden. ( Arikian, S; Arocho, R; Casciano, J; Casciano, R; Doyle, JJ; Kim, R; Kugel, H; McGuire, A; Svangren, P, 2002) |
| "The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy." | 5.51 | Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. ( Agrawal, S; Anand, J; Bachani, D; Doshi, M; Gaikwad, VB; Halder, SK; Kinholkar, B; Kumar, DA; Kumbhar, A; Mathur, R; Mehta, S; Sarkar, G; Sharma, A, 2022) |
| "Long-term therapy with a combination of perindopril and amlodipine has shown a beneficial effect on the morbidity and mortality of patients with stable coronary artery disease (SCAD) and hypertension." | 5.22 | Short-Term Cardioprotective Effects of the Original Perindopril/Amlodipine Fixed-Dose Combination in Patients with Stable Coronary Artery Disease: Results of the PAPA-CAD Study. ( Dézsi, CA; Forster, T, 2016) |
| "Amlodipine, commonly used for relief of ischemic symptoms in coronary artery disease (CAD), may affect clopidogrel-induced antiplatelet effects." | 5.20 | Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable ( Angiolillo, DJ; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Rollini, F; Rosano, G; Vitale, C, 2015) |
| "Combination therapy with benazepril 40 mg and amlodipine 10 mg (B+A) has been shown to be more effective than benazepril 40 mg and hydrochlorothiazide (HCTZ) 25 mg (B+H) in reducing cardiovascular (CV) events in high-risk patients with stage 2 hypertension with similar blood pressure reductions." | 5.17 | Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. ( Bakris, G; Briasoulis, A; Dahlof, B; Hester, A; Hua, T; Jamerson, K; Kelly, RY; Pitt, B; Weber, MA; Zappe, D, 2013) |
| "Treatment with either aliskiren or amlodipine did not significantly alter surrogate biomarkers of atherosclerosis in patients with both diabetes and established cardiovascular disease already receiving appropriate secondary cardiovascular prevention therapy." | 5.17 | Effects of direct renin inhibition on atherosclerotic biomarkers in patients with stable coronary artery disease and type 2 diabetes mellitus. ( Abo-Salem, E; Doctolero, S; Irons, BK; Meyerrose, GE; Seifert, CF; Simoni, JS; Trujillo, A, 2013) |
| "The purpose of this post hoc subgroup analysis was to compare the incidence of major adverse cardiovascular events (MACE) of patients treated with candesartan and amlodipine with that of those with candesartan and non-amlodipine CCBs in hypertensive patients with coronary artery disease (CAD)." | 5.17 | Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study. ( Hagiwara, N; Haruta, S; Kawada-Watanabe, E; Koyanagi, R; Ogawa, H; Takagi, A; Yamaguchi, J, 2013) |
| "The study was a randomized controlled trial of 2 antihypertensives (amlodipine and enalapril) compared with placebo in patients with coronary artery disease and diastolic blood pressure less than 100 mm Hg." | 5.16 | Relationship of antihypertensive treatment to plasma markers of vascular inflammation and remodeling in the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis study. ( Ganz, P; Kinlay, S; Libby, P; Nicholls, SJ; Nissen, SE; Rifai, N; Sutradhar, SC; Zamani, P, 2012) |
| "A previous study reported that amlodipine retarded coronary plaque progression in patients with coronary artery disease." | 5.15 | Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J). ( Daida, H; Fujiwara, Y; Hiro, T; Inoue, K; Kawamura, M; Kojima, T; Komiyama, N; Kurata, T; Miyauchi, K; Nakazato, Y; Okazaki, S; Sumiyoshi, M; Suwa, S; Tamura, H; Tanimoto, K; Yamagami, S; Yokoyama, K; Yokoyama, T, 2011) |
| "In many countries, combination therapy with amlodipine and atorvastatin is indicated for the treatment of patients with hypertension and hypercholesterolemia." | 5.15 | Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: combination therapy and adiponectin. ( Cheung, BM; Lam, KS; Li, M; Tse, HF; Xu, A, 2011) |
| "To estimate the potential savings in overall cardiovascular disease (CVD) treatment costs for the US population with coronary artery disease (CAD) resulting from the use of amlodipine." | 5.10 | Economic benefits of amlodipine treatment in patients with coronary artery disease. ( Arikian, S; Arocho, R; Casciano, J; Casciano, R; Chen, J; Doyle, JJ; Kugel, H, 2002) |
| "The Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES) is a multicentre, double-blind, placebo controlled restenosis trial investigating the effect of amlodipine on angiographic and clinical endpoints in patients undergoing routine percutaneous transluminal coronary angioplasty (PTCA) for stable angina pectoris." | 5.09 | Results and clinical implications of the CAPARES trial. ( Jorgensen, B; Thaulow, E, 2000) |
| "The Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) was a multicenter, randomized, placebo-controlled, double-masked clinical trial designed to test whether amlodipine would slow the progression of early coronary atherosclerosis in 825 patients with angiographically documented coronary artery disease." | 5.09 | Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. ( Byington, RP; Furberg, CD; Hunninghake, DB; Mancini, GB; Miller, ME; Pitt, B; Riley, W, 2000) |
| "To review the pharmacoeconomic impact of the use of amlodipine in coronary artery disease (CAD) patients." | 4.85 | Amlodipine: a pharmacoeconomic review. ( de Portu, S; Mantovani, LG, 2009) |
| "A literature search was performed in PubMed/MEDLINE to identify articles published in English between 1988 and March 2008 describing clinical trials, particularly outcome trials, or mechanisms of therapeutic action relevant to the use of combination therapy in patients with hypertension or stable coronary artery disease with an ACE inhibitor (perindopril) and a calcium channel blocker (amlodipine)." | 4.84 | Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine. ( Ferrari, R, 2008) |
| "In the present quantitative overview of outcome trials, we investigated the efficacy of amlodipine or angiotensin receptor blockers in the prevention of stroke and myocardial infarction in patients with hypertension, coronary artery disease, or diabetic nephropathy." | 4.84 | Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. ( Franklin, SS; Li, Y; Safar, M; Wang, JG, 2007) |
| "to compare the antianginal and pulse slowing effects, the impact on the ectopic myocardial activity as well as the safety of the treatment with beta - adrenoblocker bisoprolol, calcium antagonist verapamil and the combination of bisoprolol with amlodipine in patients with stable angina (SA) and bronchial asthma (BA)." | 3.91 | [Possibilities of cardioselective beta - blocker bisoprolol therapy in patients having coronary artery disease and bronchial asthma]. ( Grigorieva, NY; Ilyushina, TP; Yashina, EM, 2019) |
| "This study assessed adherence to and the safety, tolerance, and effectiveness of the perindopril/amlodipine FDC in Greek patients with hypertension and stable coronary artery disease (CAD) over a 4-month period." | 3.85 | Adherence to Treatment, Safety, Tolerance, and Effectiveness of Perindopril/Amlodipine Fixed-Dose Combination in Greek Patients with Hypertension and Stable Coronary Artery Disease: A Pan-Hellenic Prospective Observational Study of Daily Clinical Practice ( Kotsis, VT; Liakos, CI; Papadopoulos, DP, 2017) |
| "The objective of this analysis was to calculate the cost-effectiveness of amlodipine therapy in patients with coronary artery disease in Sweden." | 3.71 | A cost-effectiveness evaluation of amlodipine usage in patients with coronary artery disease in Sweden. ( Arikian, S; Arocho, R; Casciano, J; Casciano, R; Doyle, JJ; Kim, R; Kugel, H; McGuire, A; Svangren, P, 2002) |
| " In the prospective Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial, patients were randomized to valsartan or amlodipine regimens and followed for 4." | 2.82 | No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. ( Bangalore, S; Berge, E; Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Mancia, G; Messerli, FH; Weber, MA; Zanchetti, A; Zappe, D, 2016) |
| "Amlodipine was associated with a mean blood pressure reduction of 8/3 mm Hg (P<0." | 2.73 | Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX). ( Anderson, TJ; Buithieu, J; Chan, S; Charbonneau, F; Genest, J; Hutchison, S; Huyhn, T; Jobin, J; Lonn, E; Poirier, P; Title, L; Tran, T; Walling, A, 2008) |
| "Amlodipine also was associated with significant slowing of carotid atherosclerosis, an important surrogate marker for CAD, independent of blood pressure modification." | 2.41 | Mechanisms of plaque stabilization for a charged calcium channel blocker in coronary artery disease. ( Mason, RP, 2001) |
| "Hypertension and dyslipidemia are highly co-prevalent, but often poorly controlled, coronary heart disease (CHD) risk factors." | 1.36 | Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice. ( Chen, L; Eaddy, M; Jackson, JH; Kean, AJ; Lunacsek, OE; Neutel, JM; Roberts, C, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (6.78) | 18.2507 |
| 2000's | 30 (50.85) | 29.6817 |
| 2010's | 23 (38.98) | 24.3611 |
| 2020's | 2 (3.39) | 2.80 |
| Authors | Studies |
|---|---|
| Sarkar, G | 1 |
| Gaikwad, VB | 1 |
| Sharma, A | 1 |
| Halder, SK | 1 |
| Kumar, DA | 1 |
| Anand, J | 1 |
| Agrawal, S | 1 |
| Kumbhar, A | 1 |
| Kinholkar, B | 1 |
| Mathur, R | 1 |
| Doshi, M | 1 |
| Bachani, D | 1 |
| Mehta, S | 1 |
| Grigorieva, NY | 1 |
| Ilyushina, TP | 1 |
| Yashina, EM | 1 |
| Foley, M | 1 |
| Rajkumar, CA | 1 |
| Shun-Shin, M | 1 |
| Ganesananthan, S | 1 |
| Seligman, H | 1 |
| Howard, J | 1 |
| Nowbar, AN | 1 |
| Keeble, TR | 1 |
| Davies, JR | 1 |
| Tang, KH | 1 |
| Gerber, R | 1 |
| O'Kane, P | 1 |
| Sharp, ASP | 1 |
| Petraco, R | 1 |
| Malik, IS | 1 |
| Nijjer, S | 1 |
| Sen, S | 1 |
| Francis, DP | 1 |
| Al-Lamee, R | 1 |
| Liakos, CI | 1 |
| Papadopoulos, DP | 1 |
| Kotsis, VT | 1 |
| Dézsi, CA | 2 |
| Sakata, K | 2 |
| Gamou, T | 2 |
| Tada, H | 2 |
| Hayashi, K | 2 |
| Ino, H | 2 |
| Yamagishi, M | 2 |
| Bakris, G | 1 |
| Briasoulis, A | 1 |
| Dahlof, B | 1 |
| Jamerson, K | 1 |
| Weber, MA | 2 |
| Kelly, RY | 1 |
| Hester, A | 1 |
| Hua, T | 1 |
| Zappe, D | 2 |
| Pitt, B | 5 |
| Irons, BK | 1 |
| Trujillo, A | 1 |
| Seifert, CF | 1 |
| Simoni, JS | 1 |
| Doctolero, S | 1 |
| Abo-Salem, E | 1 |
| Meyerrose, GE | 1 |
| Koyanagi, R | 2 |
| Hagiwara, N | 2 |
| Yamaguchi, J | 2 |
| Kawada-Watanabe, E | 1 |
| Haruta, S | 1 |
| Takagi, A | 2 |
| Ogawa, H | 2 |
| Kawashiri, MA | 1 |
| Kanaya, H | 1 |
| Miwa, K | 1 |
| Ueda, K | 1 |
| Higashikata, T | 1 |
| Mizuno, S | 1 |
| Michishita, I | 1 |
| Namura, M | 1 |
| Nitta, Y | 1 |
| Katsuda, S | 1 |
| Okeie, K | 1 |
| Hirase, H | 1 |
| Uchiyama, K | 1 |
| Konno, T | 1 |
| Nagase, K | 1 |
| Terashima, M | 1 |
| Pelliccia, F | 1 |
| Greco, C | 1 |
| Gaudio, C | 1 |
| Rosano, G | 1 |
| Vitale, C | 1 |
| Marazzi, G | 1 |
| Rollini, F | 1 |
| Angiolillo, DJ | 1 |
| Kjeldsen, SE | 1 |
| Berge, E | 1 |
| Bangalore, S | 1 |
| Messerli, FH | 1 |
| Mancia, G | 1 |
| Holzhauer, B | 1 |
| Hua, TA | 1 |
| Zanchetti, A | 1 |
| Julius, S | 1 |
| Panov, AV | 1 |
| Alugishvili, MZ | 1 |
| Abesadze, IT | 1 |
| Lohovinina, NL | 1 |
| Korzenewskaya, KV | 1 |
| Titenkov, IV | 1 |
| Kuleshova, EV | 1 |
| Dyplyakov, DV | 1 |
| Hohlunov, SM | 1 |
| Kryukov, AV | 1 |
| Libis, RA | 1 |
| Isayeva, EN | 1 |
| Basyrova, IR | 1 |
| Safonova, DV | 1 |
| Forster, T | 1 |
| Kim, JS | 1 |
| Park, S | 2 |
| Yan, P | 2 |
| Jeffers, BW | 2 |
| Cerezo, C | 2 |
| Veeraputhiran, M | 1 |
| Sundermeyer, M | 1 |
| Ferrari, R | 1 |
| de Portu, S | 3 |
| Mantovani, LG | 3 |
| Miyauchi, K | 3 |
| Kojima, T | 2 |
| Yokoyama, T | 2 |
| Kurata, T | 2 |
| Yokoyama, K | 2 |
| Kawamura, M | 2 |
| Suwa, S | 2 |
| Okazaki, S | 2 |
| Inoue, K | 2 |
| Fujiwara, Y | 2 |
| Sumiyoshi, M | 2 |
| Tanimoto, K | 2 |
| Nakazato, Y | 2 |
| Yamagami, S | 2 |
| Daida, H | 3 |
| Neutel, JM | 1 |
| Eaddy, M | 1 |
| Lunacsek, OE | 1 |
| Roberts, C | 1 |
| Chen, L | 1 |
| Kean, AJ | 1 |
| Jackson, JH | 1 |
| Kasanuki, H | 1 |
| Mori, F | 1 |
| Nagashima, M | 1 |
| Yagi, M | 1 |
| Tamura, H | 1 |
| Hiro, T | 1 |
| Komiyama, N | 1 |
| Ma, J | 1 |
| Morita, T | 1 |
| Kaneda, H | 1 |
| Ueshima, K | 1 |
| Oba, K | 1 |
| Yasuno, S | 1 |
| Fujimoto, A | 1 |
| Tanaka, S | 1 |
| Ogihara, T | 1 |
| Saruta, T | 1 |
| Nakao, K | 1 |
| Li, M | 1 |
| Xu, A | 1 |
| Lam, KS | 1 |
| Cheung, BM | 1 |
| Tse, HF | 1 |
| Mourad, JJ | 1 |
| Zamani, P | 1 |
| Ganz, P | 1 |
| Libby, P | 2 |
| Sutradhar, SC | 1 |
| Rifai, N | 1 |
| Nicholls, SJ | 1 |
| Nissen, SE | 3 |
| Kinlay, S | 1 |
| Casciano, R | 2 |
| Doyle, JJ | 2 |
| Chen, J | 1 |
| Arikian, S | 2 |
| Casciano, J | 2 |
| Kugel, H | 2 |
| Arocho, R | 2 |
| Mancini, GB | 5 |
| Deanfield, JE | 1 |
| Tuzcu, EM | 2 |
| Thompson, PD | 1 |
| Ghali, M | 1 |
| Garza, D | 1 |
| Berman, L | 1 |
| Shi, H | 1 |
| Buebendorf, E | 1 |
| Topol, EJ | 1 |
| Dorval, JF | 1 |
| Anderson, T | 1 |
| Buithieu, J | 2 |
| Chan, S | 2 |
| Hutchison, S | 2 |
| Huynh, T | 1 |
| Jobin, J | 2 |
| Lonn, E | 2 |
| Poirier, P | 2 |
| Title, L | 2 |
| Walling, A | 2 |
| Tran, T | 2 |
| Boudreau, G | 1 |
| Charbonneau, F | 2 |
| Genest, J | 2 |
| Chikamori, T | 1 |
| Tomiyama, H | 1 |
| Yamashina, A | 1 |
| Aboyans, V | 1 |
| Lacroix, P | 1 |
| Cassat, C | 1 |
| Stone, PH | 1 |
| Rossetti, F | 1 |
| Menditto, E | 2 |
| Scalone, L | 2 |
| Bustacchini, S | 2 |
| Cricelli, C | 2 |
| Sorop, O | 1 |
| Bakker, EN | 1 |
| Pistea, A | 1 |
| Spaan, JA | 1 |
| VanBavel, E | 1 |
| Brener, SJ | 1 |
| Ivanc, TB | 1 |
| Poliszczuk, R | 1 |
| Chen, M | 1 |
| Hu, T | 1 |
| Frid, DJ | 1 |
| Wang, JG | 1 |
| Li, Y | 1 |
| Franklin, SS | 1 |
| Safar, M | 1 |
| Anderson, TJ | 1 |
| Huyhn, T | 1 |
| Byington, RP | 2 |
| Miller, ME | 3 |
| Herrington, D | 1 |
| Riley, W | 2 |
| Furberg, CD | 3 |
| Hunninghake, DB | 2 |
| Kramsch, DM | 1 |
| Atkinson, JB | 1 |
| Henderson, J | 1 |
| Fox, KM | 1 |
| Thaulow, E | 1 |
| Jorgensen, B | 1 |
| Jeong, MH | 1 |
| Park, JC | 2 |
| Rhew, JY | 1 |
| Kang, KT | 1 |
| Lee, SH | 1 |
| Cho, JH | 1 |
| Kim, NH | 1 |
| Kim, KH | 1 |
| Ahn, YK | 1 |
| Bae, Y | 1 |
| Cho, JG | 1 |
| Kim, SH | 1 |
| Kang, JC | 1 |
| Vita, JA | 1 |
| Yeung, AC | 1 |
| Winniford, M | 1 |
| Goldstein, MR | 1 |
| Mason, RP | 1 |
| Pieper, JA | 1 |
| Williams, C | 1 |
| McGuire, A | 1 |
| Svangren, P | 1 |
| Kim, R | 1 |
| Evans, GW | 1 |
| Byington, R | 1 |
| Cathomas, G | 1 |
| Erne, P | 1 |
| Schwenkglenks, M | 1 |
| Szucs, TD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Defining a Gold Standard for Ischaemia: Effects of Interventional Revascularisation Versus Optimum Medical Therapy on Exercise Capacity in Patients With Stable Coronary Artery Disease[NCT02062593] | 230 participants (Actual) | Interventional | 2013-12-31 | Completed | |||
| Azelnidipine and Amlodipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients Undergoing Coronary Intervention by Serial Volumetric Intravascular Ultrasound Analysis in Junten Medical University (ALPS-J)[NCT00294567] | Phase 4 | 199 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02062593)
Timeframe: 6 weeks
| Intervention | seconds (Mean) |
|---|---|
| Coronary Angioplasty and Optimum Medical Therapy | 28.4 |
| Sham Procedure and Optimum Medical Therapy | 11.8 |
10 reviews available for amlodipine and Coronary Artery Disease
| Article | Year |
|---|---|
Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Clinical Trials as T | 2008 |
Amlodipine: a pharmacoeconomic review.
Topics: Amlodipine; Antihypertensive Agents; Coronary Artery Disease; Economics, Pharmaceutical; Humans | 2009 |
Which patients benefit the most from the perindopril/amlodipine combination.
Topics: Amlodipine; Antihypertensive Agents; Clinical Trials as Topic; Coronary Artery Disease; Humans; Hype | 2011 |
ST-segment analysis in ambulatory ECG (AECG or Holter) monitoring in patients with coronary artery disease: clinical significance and analytic techniques.
Topics: Adrenergic beta-Antagonists; Amlodipine; Cardiovascular Agents; Coronary Artery Disease; Diltiazem; | 2005 |
Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Coronary Artery | 2007 |
Limits of lipid-lowering therapy: the potential benefits of amlodipine as an antiatherosclerotic agent.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cholesterol, LDL; Coronary Artery Disease; Drug Thera | 1997 |
Accelerated arteriosclerosis after transplantation: the possible role of calcium channel blockers.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Coronary Artery Disease; Coronary Vessels; Diltiazem; | 1997 |
Overview of the prospective randomized evaluation of the vascular effects of Norvasc (amlodipine) trial: PREVENT.
Topics: Amlodipine; Calcium Channel Blockers; Carotid Artery Diseases; Coronary Angiography; Coronary Artery | 2000 |
Mechanisms of plaque stabilization for a charged calcium channel blocker in coronary artery disease.
Topics: Amlodipine; Calcium Channel Blockers; Coronary Artery Disease; Coronary Disease; Endothelium, Vascul | 2001 |
Management of coronary heart disease risk factors and progression with calcium channel blockers.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Ar | 2001 |
24 trials available for amlodipine and Coronary Artery Disease
| Article | Year |
|---|---|
Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Coronary Artery Disease; | 2022 |
Achieving Optimal Medical Therapy: Insights From the ORBITA Trial.
Topics: Amlodipine; Bisoprolol; Cardiovascular Agents; Coronary Angiography; Coronary Artery Disease; Dose-R | 2021 |
Low Baseline High-Sensitive C-Reactive Protein is Associated with Coronary Atherosclerosis Regression: Insights from the MILLION Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Coronary Ar | 2019 |
Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Coronary Artery Disease; Double-Blind Metho | 2013 |
Effects of direct renin inhibition on atherosclerotic biomarkers in patients with stable coronary artery disease and type 2 diabetes mellitus.
Topics: Aged; Amides; Amlodipine; Atherosclerosis; Biomarkers; Blood Pressure; Coronary Artery Disease; Diab | 2013 |
Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Calcium Chan | 2013 |
Impact of combined lipid lowering with blood pressure control on coronary plaque regression: rationale and design of MILLION study.
Topics: Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Coronary Angiography; Coronary Ar | 2015 |
Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Blood Platelets; Coronary Artery Disease; Dr | 2015 |
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Coronary Ar | 2016 |
[The Antihypertensive Effect of the Fixed Combination of Lisinopril and Amlodipine in Patients With Coronary Heart Disease After Coronary Artery Bypass Grafting].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Artery Bypass; Coronary A | 2015 |
Short-Term Cardioprotective Effects of the Original Perindopril/Amlodipine Fixed-Dose Combination in Patients with Stable Coronary Artery Disease: Results of the PAPA-CAD Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ca | 2016 |
Effect of inter-individual blood pressure variability on the progression of atherosclerosis in carotid and coronary arteries: a post hoc analysis of the NORMALISE and PREVENT studies.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosi | 2017 |
Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo university (ALPS-J).
Topics: Adult; Aged; Amlodipine; Azetidinecarboxylic Acid; Calcium Channel Blockers; Coronary Artery Disease | 2009 |
Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angina, Unstable; Angiotensin II Type 1 Receptor Blocker | 2010 |
Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J).
Topics: Amlodipine; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Coronary Artery Dise | 2011 |
Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: combination therapy and adiponectin.
Topics: Adiponectin; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; | 2011 |
Relationship of antihypertensive treatment to plasma markers of vascular inflammation and remodeling in the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis study.
Topics: Amlodipine; Antihypertensive Agents; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Corona | 2012 |
[Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo Medical University].
Topics: Aged; Amlodipine; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Coronary Arter | 2012 |
Economic benefits of amlodipine treatment in patients with coronary artery disease.
Topics: Amlodipine; Calcium Channel Blockers; Coronary Artery Disease; Cost Savings; Female; Humans; Male; M | 2002 |
Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensi | 2004 |
Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Canada; Cholesterol; Cholesterol, | 2005 |
Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX).
Topics: Adult; Aged; Amlodipine; Apolipoproteins B; Atorvastatin; Biomarkers; Blood Pressure; Brachial Arter | 2008 |
Results and clinical implications of the CAPARES trial.
Topics: Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Coronary Angi | 2000 |
Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators.
Topics: Aged; Amlodipine; Calcium Channel Blockers; Coronary Artery Disease; Double-Blind Method; Female; Hu | 2000 |
25 other studies available for amlodipine and Coronary Artery Disease
| Article | Year |
|---|---|
[Possibilities of cardioselective beta - blocker bisoprolol therapy in patients having coronary artery disease and bronchial asthma].
Topics: Adrenergic beta-Antagonists; Amlodipine; Asthma; Bisoprolol; Coronary Artery Disease; Humans | 2019 |
Adherence to Treatment, Safety, Tolerance, and Effectiveness of Perindopril/Amlodipine Fixed-Dose Combination in Greek Patients with Hypertension and Stable Coronary Artery Disease: A Pan-Hellenic Prospective Observational Study of Daily Clinical Practice
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; | 2017 |
Treatment with triple combination of atorvastatin, perindopril, and amlodipine in patients with stable coronary artery disease: A subgroup analysis from the PAPA-CAD study.
Topics: Amlodipine; Atorvastatin; Blood Pressure; Coronary Artery Disease; Drug Combinations; Electrocardiog | 2018 |
Effect of visit-to-visit blood pressure variability on cardiovascular events in patients with coronary artery disease and well-controlled blood pressure.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Cardiovascu | 2016 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensiv | 2008 |
Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium | 2010 |
Intravascular ultrasound parameters in non-inferiority trial.
Topics: Amlodipine; Azetidinecarboxylic Acid; Coronary Artery Disease; Dihydropyridines; Humans; Hypertensio | 2011 |
Influence of coronary risk factors on coronary events in Japanese high-risk hypertensive patients. - Primary and secondary prevention of ischemic heart disease in a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) tria
Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl Compounds; Coronar | 2011 |
Coronary angiographic changes in patients with cardiac events in the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT).
Topics: Amlodipine; Calcium Channel Blockers; Coronary Angiography; Coronary Artery Disease; Disease Progres | 2002 |
Targeting the atherosclerotic process in clinical practice. A new look at established agents.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Chan | 2002 |
Antihypertensive agents and cardiovascular events in patients with coronary disease and normal blood pressure.
Topics: Amlodipine; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calc | 2005 |
Antihypertensive agents and cardiovascular events in patients with coronary disease and normal blood pressure.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2005 |
Pharmacoeconomic consequences of amlodipine besylate therapy in patients undergoing PTCA.
Topics: Amlodipine; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Coronary Restenosis; Cost-Benef | 2006 |
Calcium channel blockade prevents pressure-dependent inward remodeling in isolated subendocardial resistance vessels.
Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Coronary Artery Disease; Coronary Ste | 2006 |
The pharmacoeconomic impact of amlodipine use on coronary artery disease.
Topics: Adult; Aged; Amlodipine; Calcium Channel Blockers; Coronary Artery Disease; Cost-Benefit Analysis; C | 2006 |
Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular So
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2006 |
Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT).
Topics: Aged; Amlodipine; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Double-Blind Meth | 1997 |
Can calcium antagonists reverse atherosclerosis?
Topics: Amlodipine; Calcium Channel Blockers; Coronary Artery Disease; Disease Progression; Humans | 1999 |
Successful management of intractable coronary spasm with a coronary stent.
Topics: Adult; Amlodipine; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Coronary Angiography; C | 2000 |
Coronary artery reactivity after treatment with simvastatin.
Topics: Amlodipine; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary V | 2001 |
Does amlodipine increase cancer incidence?
Topics: Amlodipine; Calcium Channel Blockers; Coronary Artery Disease; Disease Progression; Humans; Incidenc | 2001 |
Amlodipine PREVENTS angina, not atherosclerosis.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Coronary Artery Disease; Coronary Disease; Di | 2002 |
A cost-effectiveness evaluation of amlodipine usage in patients with coronary artery disease in Sweden.
Topics: Amlodipine; Analysis of Variance; Calcium Channel Blockers; Cohort Studies; Coronary Artery Disease; | 2002 |
Post hoc analysis of coronary findings from the prospective randomized evaluation of the vascular effects of the Norvasc trial (PREVENT).
Topics: Amlodipine; Calcium Channel Blockers; Coronary Angiography; Coronary Artery Disease; Coronary Diseas | 2002 |
The economic efficiency of amlodipine in the treatment of coronary atherosclerosis--an analysis based on the PREVENT study.
Topics: Amlodipine; Calcium Channel Blockers; Coronary Artery Disease; Cost-Benefit Analysis; Economics, Pha | 2002 |